Merck (MRK) Misses Q4 EPS by 9c; misses on outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Merck (MRK) PT Lowered to $129 at Goldman Sachs
February 5, 2025 6:35 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on Merck (NYSE: MRK) to $129.00 (from $135.00) while maintaining a Buy rating.
The analyst comments "Amidst a backdrop where MRK delivered strong operational performance across the majority of the company's key franchises, the announcement of 2025 guidance, highlighted by the negative impact of the nettlesome dynamics for... More
